IL150516A0 - The use of fumaric acid derivatives for treatment of mitochondrial diseases - Google Patents
The use of fumaric acid derivatives for treatment of mitochondrial diseasesInfo
- Publication number
- IL150516A0 IL150516A0 IL15051600A IL15051600A IL150516A0 IL 150516 A0 IL150516 A0 IL 150516A0 IL 15051600 A IL15051600 A IL 15051600A IL 15051600 A IL15051600 A IL 15051600A IL 150516 A0 IL150516 A0 IL 150516A0
- Authority
- IL
- Israel
- Prior art keywords
- fumaric acid
- treatment
- mitochondrial diseases
- acid derivatives
- sdh
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 3
- 150000002237 fumaric acid derivatives Chemical class 0.000 title abstract 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 abstract 4
- 108010012901 Succinate Dehydrogenase Proteins 0.000 abstract 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 230000010627 oxidative phosphorylation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10000577A DE10000577A1 (de) | 2000-01-10 | 2000-01-10 | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| PCT/EP2000/012504 WO2001051047A1 (de) | 2000-01-10 | 2000-12-11 | Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL150516A0 true IL150516A0 (en) | 2003-02-12 |
Family
ID=7627026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15051600A IL150516A0 (en) | 2000-01-10 | 2000-12-11 | The use of fumaric acid derivatives for treatment of mitochondrial diseases |
| IL150516A IL150516A (en) | 2000-01-10 | 2002-07-02 | 3, 4 - epoxy alkanoic acid ester, fragrant component, fragrant product containing those, and application of those compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL150516A IL150516A (en) | 2000-01-10 | 2002-07-02 | 3, 4 - epoxy alkanoic acid ester, fragrant component, fragrant product containing those, and application of those compounds |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6858750B2 (cs) |
| EP (1) | EP1248606B1 (cs) |
| JP (1) | JP2003529556A (cs) |
| CN (1) | CN1433303A (cs) |
| AT (1) | ATE329590T1 (cs) |
| AU (1) | AU772409B2 (cs) |
| BG (1) | BG65468B1 (cs) |
| BR (1) | BR0016935A (cs) |
| CA (1) | CA2390886C (cs) |
| CY (1) | CY1105462T1 (cs) |
| CZ (1) | CZ303680B6 (cs) |
| DE (2) | DE10000577A1 (cs) |
| DK (1) | DK1248606T3 (cs) |
| EE (1) | EE05051B1 (cs) |
| ES (1) | ES2265367T3 (cs) |
| HU (1) | HU229138B1 (cs) |
| IL (2) | IL150516A0 (cs) |
| MX (1) | MXPA02006695A (cs) |
| NO (1) | NO326875B1 (cs) |
| NZ (1) | NZ518781A (cs) |
| PL (1) | PL223342B1 (cs) |
| PT (1) | PT1248606E (cs) |
| RS (1) | RS50185B (cs) |
| RU (1) | RU2218918C1 (cs) |
| SI (1) | SI1248606T1 (cs) |
| SK (1) | SK286719B6 (cs) |
| WO (1) | WO2001051047A1 (cs) |
| ZA (1) | ZA200205481B (cs) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| AU2002219236B2 (en) | 2001-01-12 | 2006-02-09 | Biogen International Gmbh | Fumaric acid amides |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| US7224426B2 (en) * | 2002-07-31 | 2007-05-29 | Dai Nippon Printing Co., Ltd. | Optical element |
| CA2526586C (en) * | 2003-09-09 | 2010-03-16 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| EP1799196B1 (en) * | 2004-10-08 | 2016-06-22 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| AU2007328210B2 (en) * | 2006-12-06 | 2012-11-22 | Cornell Research Foundation, Inc. | Intermediate duration neuromuscular blocking agents and antagonists thereof |
| EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| EP2139467B1 (en) * | 2007-02-08 | 2016-09-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| JP2012514623A (ja) * | 2009-01-09 | 2012-06-28 | フォーワード・ファルマ・アクティーゼルスカブ | １またはそれ以上のフマル酸エステルを含む医薬組成物 |
| UA125896C2 (uk) * | 2009-01-09 | 2022-07-06 | Фвп Іп Апс | Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти |
| WO2010107488A1 (en) | 2009-03-17 | 2010-09-23 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| WO2011022491A1 (en) | 2009-08-19 | 2011-02-24 | Cornell University | Cysteine for physiological injection |
| CA2865316A1 (en) * | 2011-04-28 | 2012-11-01 | Gino Cortopassi | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| NZ618178A (en) | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
| EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| TWI486339B (zh) | 2012-02-07 | 2015-06-01 | Xenoport Inc | □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法 |
| CN114146079A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP6506174B2 (ja) | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| CA2992211C (en) | 2013-03-14 | 2021-09-21 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| AU2015218587B2 (en) | 2014-02-24 | 2017-04-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| SG10201907289VA (en) | 2015-02-08 | 2019-09-27 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
| DK3273951T3 (da) | 2015-03-27 | 2020-11-02 | Symbionyx Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af psoriasis |
| EP3302461A4 (en) | 2015-06-01 | 2019-02-13 | Sun Pharmaceutical Industries Ltd | PHARMACEUTICAL COMPOSITIONS OF DIMETHYLFUMARATE |
| WO2017060420A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| RU2674286C1 (ru) * | 2018-03-20 | 2018-12-07 | Исмагилов Искандар Халиуллович | Средство для лечения заболевания, обусловленного нарушением окислительного стресса |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3832287A (en) | 1972-03-02 | 1974-08-27 | Lilly Co Eli | Dipeptide antibiotic and method for the production thereof |
| DE2530372A1 (de) | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| DE3127432A1 (de) | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| US5149695A (en) | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
| JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
| IL83775A (en) | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
| US5242905A (en) | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US5214196A (en) | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
| WO1992012952A1 (en) | 1991-01-18 | 1992-08-06 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| IT1251166B (it) | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| DE4494231T1 (de) | 1993-06-08 | 1996-10-17 | Raymond K Brown | Therapeutische Zusammensetzung und ihre Anwendung |
| US5407772A (en) | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| JPH09510222A (ja) | 1994-03-16 | 1997-10-14 | ノボ ノルディスク アクティーゼルスカブ | ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩 |
| IL110380A0 (en) | 1994-07-20 | 1994-10-21 | Agis Ind 1983 Ltd | Antiviral topical pharmaceutical compositions |
| US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| ATE253057T1 (de) | 1994-08-30 | 2003-11-15 | Sankyo Co | Isoxazole |
| US6011000A (en) | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
| HU9502843D0 (en) | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| EP0885891A4 (en) | 1996-02-27 | 2001-02-21 | Sankyo Co | ISOXAZOLE DERIVATIVES |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| AU7003096A (en) | 1996-06-21 | 1998-01-07 | Jury Evgenievich Belyaev | Semi-finished product for producing drug bases, bases obtained using the same and variants, and drugs obtained using these bases and variants |
| EP1611885A1 (en) | 1996-07-26 | 2006-01-04 | Susan P. Perrine | Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| WO1998027970A2 (en) | 1996-12-24 | 1998-07-02 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| US5972363A (en) | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| RU2136291C1 (ru) * | 1998-02-02 | 1999-09-10 | Российский научно-исследовательский институт гематологии и трансфузиологии | Полифункциональный кровезаменитель для лечения кровопотери и шока |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| RU2132187C1 (ru) * | 1998-11-12 | 1999-06-27 | Антипов Борис Геннадиевич | Способ лечения заболеваний кожи и слизистых оболочек и магнитоактивное органическое соединение железа, используемое в нем |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| RU2160589C1 (ru) | 2000-05-18 | 2000-12-20 | Алекс Кашлинский | Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
-
2000
- 2000-01-10 DE DE10000577A patent/DE10000577A1/de not_active Withdrawn
- 2000-12-11 MX MXPA02006695A patent/MXPA02006695A/es active IP Right Grant
- 2000-12-11 AU AU31566/01A patent/AU772409B2/en not_active Ceased
- 2000-12-11 CN CN00818784A patent/CN1433303A/zh active Pending
- 2000-12-11 PT PT00991160T patent/PT1248606E/pt unknown
- 2000-12-11 AT AT00991160T patent/ATE329590T1/de active
- 2000-12-11 EP EP00991160A patent/EP1248606B1/de not_active Expired - Lifetime
- 2000-12-11 EE EEP200200333A patent/EE05051B1/xx not_active IP Right Cessation
- 2000-12-11 DE DE50013000T patent/DE50013000D1/de not_active Expired - Lifetime
- 2000-12-11 IL IL15051600A patent/IL150516A0/xx active IP Right Grant
- 2000-12-11 BR BR0016935-8A patent/BR0016935A/pt not_active Application Discontinuation
- 2000-12-11 JP JP2001551471A patent/JP2003529556A/ja active Pending
- 2000-12-11 RS YUP-514/02A patent/RS50185B/sr unknown
- 2000-12-11 CZ CZ20021522A patent/CZ303680B6/cs not_active IP Right Cessation
- 2000-12-11 RU RU2002121493/15A patent/RU2218918C1/ru not_active IP Right Cessation
- 2000-12-11 SK SK652-2002A patent/SK286719B6/sk not_active IP Right Cessation
- 2000-12-11 CA CA002390886A patent/CA2390886C/en not_active Expired - Fee Related
- 2000-12-11 DK DK00991160T patent/DK1248606T3/da active
- 2000-12-11 NZ NZ518781A patent/NZ518781A/en not_active IP Right Cessation
- 2000-12-11 PL PL356714A patent/PL223342B1/pl unknown
- 2000-12-11 HU HU0204182A patent/HU229138B1/hu not_active IP Right Cessation
- 2000-12-11 US US10/148,858 patent/US6858750B2/en not_active Expired - Lifetime
- 2000-12-11 ES ES00991160T patent/ES2265367T3/es not_active Expired - Lifetime
- 2000-12-11 SI SI200030869T patent/SI1248606T1/sl unknown
- 2000-12-11 WO PCT/EP2000/012504 patent/WO2001051047A1/de not_active Ceased
-
2002
- 2002-05-07 NO NO20022175A patent/NO326875B1/no not_active IP Right Cessation
- 2002-05-09 BG BG106685A patent/BG65468B1/bg unknown
- 2002-07-02 IL IL150516A patent/IL150516A/en not_active IP Right Cessation
- 2002-07-09 ZA ZA200205481A patent/ZA200205481B/xx unknown
-
2006
- 2006-08-11 CY CY20061101141T patent/CY1105462T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150516A0 (en) | The use of fumaric acid derivatives for treatment of mitochondrial diseases | |
| UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
| BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
| NZ514234A (en) | N-cyanomethylamides as protease inhibitors | |
| TR199801642T2 (xx) | Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri. | |
| IL148103A0 (en) | Novel dicarboxylic acid derivatives with pharmaceutical properties | |
| ES2103587T3 (es) | Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph. | |
| WO2003037323A3 (en) | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | |
| DE60217356D1 (de) | Creme zur behandlung von sonnengeschädigter haut | |
| MXPA02006249A (es) | Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas. | |
| ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| IL163344A (en) | 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid derivative compounds, process for their synthesis and compositions comprising the compounds as the active ingredient | |
| DE60122917D1 (de) | Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin | |
| MY122830A (en) | Process for the preparation of (alpha)-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
| DE59801192D1 (de) | Delta-aminolävulinsäure enthaltendes arzneimittel | |
| MXPA03002047A (es) | Fenilciclohexanocarboxamidas substituidas y su uso. | |
| ATE330597T1 (de) | Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens | |
| CY1106168T1 (el) | Συνθεση για την προληψη και/ή θepαπεια αγγειακων ασθενειων που συνισταται απο προπιονυλ l-καρνιτινη και συνενζυμο q10 | |
| MXPA02006673A (es) | Proceso novedoso para la preparacion de alfa-(2,4-disulfufenil)-n-ter-butilnitrona y las sales farmaceuticamente aceptables de la misma. | |
| NO20044555L (no) | Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener | |
| GR3018126T3 (en) | 4-[(Thiophene-2-carbonyl)oxy]pyrrolidine-2-carboxylic acid, its preparation and its use as anti-inflammatory and anti-dystrophic agent. | |
| UA41037A (uk) | Препарат для лікування захворювань порожнини роту | |
| YU89903A (sh) | Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |